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Objectives During its German pilot phase, the EuroCMR (European Cardiovascular Magnetic Resonance) registry sought to
evaluate indications, image quality, safety, and impact on patient management of routine CMR.
Background CMR has a broad range of applications and is increasingly used in clinical practice.
Methods This was a multicenter registry with consecutive enrollment of patients in 20 German centers.
Results A total of 11,040 consecutive patients were enrolled. Eighty-eight percent of patients received gadolinium-based
contrast agents. Twenty-one percent underwent adenosine perfusion, and 11% high-dose dobutamine-stress
CMR. The most important indications were workup of myocarditis/cardiomyopathies (32%), risk stratification in
suspected coronary artery disease/ischemia (31%), as well as assessment of viability (15%). Image quality was
good in 90.1%, moderate in 8.1%, and inadequate in 1.8% of cases. Severe complications occurred in 0.05%,
and were all associated with stress testing. No patient died during or due to CMR. In nearly two-thirds of pa-
tients, CMR findings impacted patient management. Importantly, in 16% of cases the final diagnosis based on
CMR was different from the diagnosis before CMR, leading to a complete change in management. In more than
86% of cases, CMR was capable of satisfying all imaging needs so that no further imaging was required.
Conclusions CMR is frequently performed in clinical practice in many participating centers. The most important indications
are workup of myocarditis/cardiomyopathies, risk stratification in suspected coronary artery disease/ischemia,
and assessment of viability. CMR imaging as used in the centers of the pilot registry is a safe procedure, has
diagnostic image quality in 98% of cases, and its results have strong impact on patient management. (J Am
Coll Cardiol 2009;54:1457–66) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.003C
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nardiovascular magnetic resonance (CMR) is a rapidly
merging noninvasive imaging technique providing high-
esolution images of the heart in any desired plane without
pplication of radiation (1). Rather than a single technique,
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ithout vasodilators can provide myocardial perfusion
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EuroCMR Registry Pilot Results October 6, 2009:1457–66(3–6), and contrast CMR can be
used for infarct detection, as well
as for tissue characterization (7).
CMR has a broad range of
appropriate clinical applications,
and is increasingly used in daily
clinical practice. However, de-
tailed information on the general
use of this technique in the clin-
ical routine, its safety, and its
impact on patient management is
currently not available. Thus, the
German pilot phase of the Eu-
roCMR (European Cardiovas-
ular Magnetic Resonance) registry sought to evaluate
ndications, image quality, safety, and impact on patient
anagement of routine CMR imaging in a large number of
ases to: 1) substantiate the clinical value of CMR; and
) help define clinical questions to be investigated as specific
rotocols on a European multicenter level (Fig. 1).
ethods
tudy population and data management. The basis of the
urrent paper is the German pilot phase of the EuroCMR
egistry. This registry includes 11,040 consecutive patients
ho underwent CMR in 1 of 20 participating sites (see
cknowledgments in the Online Appendix) according to
he American College of Cardiology Foundation/American
ollege of Radiology/Society of Cardiovascular Computed
Abbreviations
and Acronyms
CAD  coronary artery
disease
CMR  cardiovascular
magnetic resonance
HCM  hypertrophic
cardiomyopathy
SCMR  Society for
Cardiovascular Magnetic
Resonance
SPECT  single-photon
emission tomography
Prospective 
Clinical Trials
Guidelines
Pilot Phase
EuroCMR 
Registry
Real World CMR Experience:
Indications, Safety, Quality, Impact
EuroCMR 
Registry S d CAD
Prognostic Data Cost Effectiveness
Data   
Safety & Quality
uspecte -
HCM-SCD
CHF-Prognosis 
  
Further Specific 
Protocols
Figure 1 Registry Goals
Illustration of the role and importance of imaging registry data in the continu-
ous circle of optimizing patient management and prognosis, as well as short-
term goals and future plans for the EuroCMR (European Cardiovascular
Magnetic Resonance) registry. CAD  coronary artery disease; CHF  conges-
tive heart failure; HCM  hypertrophic cardiomyopathy; SCD  sudden cardiac
death.domography/Society for Cardiovascular Magnetic Reso-
ance (SMCR)/American Society of Nuclear Cardiology/
orth American Society for Cardiac Imaging/Society for
ardiovascular Angiography and Interventions/Society of
nterventional Radiology consensus appropriateness criteria
or CMR imaging (8). All procedures were performed in
ompliance with the standardized SCMR-recommended
rotocols (9). All data were prospectively collected by
rained personnel, manually entered in online case record
orms based on database elements provided by the “Institut
ür Herzinfarktforschung,” University of Heidelberg, Ger-
any via a secure sockets layer internet connection, and
tored on a central server. Each participating center ap-
ointed a senior investigator (either SCMR Level 3 trained,
r licensed for CMR by the German Chamber of Physi-
ians, which has stricter requirements than SCMR Level 3
2 years’ full-time training]) as local investigator responsible
or data quality of each patient entered. If necessary, this
ocal investigator contacted all sources of information nec-
ssary in order to determine more complex variables, such as
he impact of CMR on patient management. A plausibility
heck was carried out after submitting the data to minimize
urther queries. Benchmarking reports were regularly made
vailable to the local investigators for quality control. The
eports were compiled for each participating center relating
ll data of the center with those of other centers. Data
ollection and management were approved by the ethics
ommittee of the Institut für Herzinfarktforschung.
nalysis cohort. All 11,040 patients enrolled between
pril 2007 and January 2009 were included in the analysis.
uring online documentation pre-specified plausibility
hecks were performed. The completeness of the analysis
ataset was higher than 98%. For some types of analysis, the
ohort was divided in patients that underwent CMR stress
esting (n 3,475), and patients that did not undergo stress
MR (n  7,565).
ariables and definitions. All variables assessed were pre-
efined, and were collected directly from patients, and/or from
edical records. Variables include anonymous demographic
ata, history, indication for CMR, procedural parameters,
omplications, results of CMR, as well as the impact of CMR
n clinical management. Most fields are self-explanatory; all
ther fields are defined in the following paragraphs.
OMPLICATIONS OF CMR. Severe complications were de-
ned as death, resuscitation, or any other condition related
o the CMR procedure that required monitoring as an
npatient for at least 1 night after the CMR scan (e.g.,
llergic shock, arrhythmias, and so on). Mild complications
ere defined as any complications related to CMR that did
ot fulfill the criteria for severe complications (e.g., dyspnea,
hest pain, allergic reactions without shock, problems re-
ated to intravenous lines, and so forth).
MR IMAGE QUALITY. Images that did not allow answering
he question of the referrer were graded as poor. Images that
id allow complete answering of the question of the referrer,
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October 6, 2009:1457–66 EuroCMR Registry Pilot Resultsut some doubts on the findings remained due to artefacts,
ere graded as moderate. Images with optimal quality that
llowed complete answering of the question the CMR was
rdered for were graded as good.
A change of patient management was reported if CMR
esulted in a new diagnosis that was not suspected before
e.g., amyloidosis found during workup of suspected aortic
alve stenosis). Furthermore, a change of patient manage-
ent was also reported if the results of CMR initiated a
irect therapeutic consequence, such as a change in medi-
ation (e.g., start of secondary prevention after detection of
myocardial infarction), ordering of invasive procedures,
uch as coronary angiography or surgery, immediate hospital
dmission (e.g., new aortic dissection), or discharge from
he hospital (risk stratification in suspected coronary artery
isease [CAD] revealed low risk for cardiovascular events).
tatistics. Since the objectives of this registry are descrip-
ive in nature, no formal hypothesis testing was done.
bsolute numbers and percentages were computed to de-
cribe the patient population. Medians (with quartiles) or
eans (with standard deviation) were computed as appro-
riate. Categorical values were compared by chi-square test
r Fisher exact test, and continuous variables were compared
y 2-tailed Wilcoxon rank sum test. Values of p  0.05 were
onsidered significant. All p values were results of 2-tailed
ests. The tests were performed using the SAS statistical
ackage version 9.1 (SAS Inc., Cary, North Carolina).
esults
eneral use of CMR in the clinical routine and most
mportant indications. The most important indications
Figure 2 Cardiomyopathies
Steady-state free precession (left 2 columns [systole and diastole]), and contrast
ment [LGE]) of a 51-year-old male patient presenting for workup of myocardial dise
eccentric septal hypertrophy as a typical feature of hypertrophic cardiomyopathy (s
important arrhythmogenic substrate, can be visualized and quantified noninvasivelor CMR in this cohort were: 1) workup of myocarditis and
ardiomyopathies (31.9%); 2) risk stratification in suspected
AD/ischemia (30.8%); followed by 3) the assessment of
yocardial viability (14.7%). Dividing the analysis cohort in
ubgroups of internal referrals (46.7%) and external referrals
53.3%), the 3 most important indications remain: 1) workup of
yocarditis and cardiomyopathies; 2) risk stratification in sus-
ected CAD/ischemia; and 3) assessment of myocardial viability
n each of the 2 subgroups. Case examples illustrating the
apabilities of CMR regarding the most important indications can
e viewed in Figures 2 to 4. Eighty-eight percent of all patients
eceived a gadolinium-based contrast agent. The median contrast
ose was 1.28 mmol/kg [bodyweight] (1.16  1.56 mmol/kg).
aseline characteristics can be viewed in Table 1.
maging procedures before CMR. Before undergoing
MR, 64.1% of patients had undergone transthoracic echo-
ardiography, 25.1% had undergone cardiac catheterization,
.9% had undergone transesophageal echocardiography, 1.8%
ad undergone cardiac computed tomography, and 0.3% had
ndergone single-photon emission tomography (SPECT) im-
ging. In 23.1% of patients, CMR was the first imaging
rocedure ordered.
rocedural safety in the clinical routine. Nearly 99% of
ll CMR procedures (n  10,896) were performed without
omplications. Mild complications occurred in 1.1% of
atients (n  124), and severe complications in 0.05% only
n  5). In the group with mild complications, most events
e.g., dyspnea, chest pain, extra systoles, and so on) occurred
uring dobutamine or adenosine infusion (76%), followed
y mild allergic reactions after injection of contrast (e.g.,
ild urticaria or exanthema) in 22% of cases.
vascular magnetic resonance images (right column, late gadolinium enhance-
fter aborted sudden cardiac death. Short- and long-axis images clearly show
steady-state free precession). Myocardial scarring, which is suspected to be an
ntrast cardiovascular magnetic resonance (white arrows, right column, LGE).cardio
ase a
ystolic
y by co
n
fi
o
r
C
(
o
I
w
(
P
p
s
w
p
p
y
w
i
I
s
p
I
r
c
m
(
d
d
p
f
s
o
r
n
a
d
t
g
f
a
p
H
l
1460 Bruder et al. JACC Vol. 54, No. 15, 2009
EuroCMR Registry Pilot Results October 6, 2009:1457–66In the 5 patients with severe complications, we found
onsustained ventricular tachycardia (n 1) and ventricular
brillation (n  1) during dobutamine infusion, as well as
vert heart failure (n  2) and unstable angina (n  1)
elated to adenosine stress. No patient died during or due to
MR. All severe complications were related to stress testing
Table 2). Procedural safety was not dependent on race, sex,
r age of the patient.
mage quality in the clinical routine. Good image quality
as achieved in 90.1% (n  9,938) of all patients. In 8.1%
n  897), image quality was moderate but still diagnostic.
oor image quality (nondiagnostic) was present in 1.8% of
atients only (n 189). No difference was found comparing
tress to no stress CMR (good image quality in 89.9%
ithout stress vs. 90.7% with stress, p  0.22).
Image quality was not dependent on race or sex of the
atients. However, there was a significant trend toward
oorer image quality in older patients (75 years vs. 45
ears; p  0.0001). Despite this decrease of image quality
ith age, the ability of CMR to derive a diagnosis and the
mpact on patient management was not affected (Table 3).
n fact, the percentage of therapeutic consequences was even
ignificantly higher in older patients compared with younger
Figure 3 Risk Stratification in Suspected CAD
Steady-state free precession cine (diastole and systole), fast gradient echo perfus
(CMR) late gadolinium enhancement (LGE) images of a 65-year-old woman present
risk factor. She was referred to adenosine stress CMR after a normal stress elect
CMR revealed stress-induced ischemia in several coronary artery territories (top a
CMR results, invasive angiography was performed demonstrating triple-vessel coro
ization. Note the stress perfusion defects in the perfusion areas of the left anterio
significant stenosis of the corresponding coronary vessels (bottom, white arrows)atients (age 75 years vs. 45 years; p  0.0001). mmpact of CMR on patient management in the clinical
outine. In nearly two-thirds of all patients (61.8%), we
ould demonstrate direct impact of CMR on the clinical
anagement by providing an unsuspected new diagnosis
16.4%) and/or resulting in therapeutic consequences as
escribed in Tables 4 and 5.
A typical example for a completely unsuspected new
iagnosis can be viewed in Figure 5. A retired man
resented at our emergency room due to overt heart
ailure. A few weeks earlier, he had been seen with the
ame symptoms at another hospital, where the diagnosis
f severe aortic valve stenosis was made, and aortic valve
eplacement was recommended. However, the patient did
ot consent to surgery at that time and was discharged
fter medical treatment. Emergency room assessment
emonstrated global hypertrophy accentuated at the ven-
ricular septum, a slightly elevated transaortic pressure
radient, and mild aortic stenosis only. CMR was per-
ormed for workup of the discrepancies between the
ctual and the previous external findings. Based on CMR
lanimetry, the aortic stenosis was ruled to be mild.
owever, contrast CMR revealed circular subendocardial
ate gadolinium enhancement in the entire left ventricular
ress and rest), as well as contrast-enhanced cardiovascular magnetic resonance
r workup of atypical chest pain and diabetes mellitus as her only cardiovascular
iogram up to 125 W and normal echocardiography at rest. Adenosine perfusion
dle) without myocardial scarring or wall motion abnormalities. Based on the
rtery disease (bottom). The patient underwent subsequent surgical revascular-
ending (LAD), and the right coronary artery (RCA) (top, white arrows), matching
 coronary artery disease; LCX  left circumflex artery.ion (st
ing fo
rocard
nd mid
nary a
r desc
. CADyocardium, which is characteristic for cardiac amyloid-
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October 6, 2009:1457–66 EuroCMR Registry Pilot Resultssis (10). This diagnosis was confirmed by endomyocar-
ial biopsy.
In our analysis cohort, CMR was capable of satisfying all
maging needs in more than 86% of patients so that no
urther noninvasive imaging procedure was required after
MR (Table 4). In the subgroup of patients in whom CMR
as the first imaging procedure ordered (23.1%), CMR
atisfied all imaging needs in 80.3%, and also no further
oninvasive imaging procedure was required in those pa-
ients. Furthermore, in this subgroup 74.2% of CMR scans
esulted in a direct therapeutic consequence as described in
he preceding text.
Focusing on the group of patients that underwent stress
MR for workup of suspected CAD or suspected ischemia
n known CAD reveals that in nearly one-half of the cases
45%) invasive angiography could be avoided based on the
esults of CMR (Table 6).
iscussion
his dataset is unique in that it describes the clinical use,
ncluding indications, image quality, procedural safety and
mpact on patient management of CMR in a large number of
ases in an interdisciplinary, multicenter, and multivendor
etting (Online Appendix). Our data indicate that CMR is
requently performed in clinical routine, is a safe procedure, has
iagnostic image quality in more than 98% of cases, and its
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Figure 4 Myocardial Viability
Steady state free precession cine (diastole and systole), as well as contrast-enhan
angiography in the right row), and severely impaired left ventricular function prese
that only a small nontransmural anterior wall myocardial infarction is present (LGE
after surgical revascularization, the left ventricular function significantly improved (
LCA  left circumflex artery; other abbreviations as in Figure 3.esults have strong impact on patient management. reneral use of CMR in the clinical routine and most
mportant indications. In our analysis, more than 88% of
MR procedures involved the use of contrast media. This
ay relate to the unique capabilities of CMR providing
oninvasive tissue characterization (7), allowing the detec-
ion of small subendocardial infarcts (11,12), prediction of
ecovery of ventricular function before revascularization
13), risk stratification in suspected CAD (14,15), evalua-
ion of myocardial ischemia (4), as well as assessment of
ardiomyopathies (7,16–18) and myocarditis (19–21), re-
pectively. Pharmacologic stress testing using adenosine or
obutamine was applied in about one-third of cases (Table 1)
nderscoring that CMR stress testing is not a research
pplication anymore, but is widely used in clinical routine.
CMR case reading and reporting was mostly done by
ardiologists (78.2%), or a team of cardiologists and radiol-
gists (20.1%), respectively. However, this finding may be
nfluenced by a selection bias, since the registry was initiated
nd is run by a cardiologist society.
Although promising results have been reported for 3.0-T
maging, especially to improve speed (e.g., CMR perfusion),
nd/or spatial resolution (e.g., CMR coronary angiography)
22,23), CMR imaging at 3.0-T still plays a minor role in
eneral clinical practice (0.8% of studies).
Since the 3 most important CMR indications are not
ifferent in the subgroups of internal and external refer-
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ced C
nting f
, white
bottomals, a relevant bias of the registry data reflecting the
p
b
I
p
C
fi
2
g
c
P
t
0
i
t
s
t
r
8
t
n
C
c
n
t
m
c
fi
t
g
t
C
s
s
t
I
t
C
B
V
r
IC
*
1462 Bruder et al. JACC Vol. 54, No. 15, 2009
EuroCMR Registry Pilot Results October 6, 2009:1457–66riorities of the authors driven by self-referrals seems to
e unlikely.
maging procedures before CMR. About two-thirds of
atients had a prior echocardiography before undergoing
MR, which reflects the importance of echocardiography as a
rst-line imaging technique in the clinical routine. However, in
3.1% of patients CMR was the first imaging test ordered,
iving us a unique subgroup for evaluation of the diagnostic
apabilities of CMR.
rocedural safety in the clinical routine. Mild complica-
ions occurred in 1.1%, and severe complications in only
.05% of patients. No patient died during or due to CMR,
ndicating that CMR as used in the centers participating in
he registry is safe, when performed in a routine clinical
etting. All severe complications were related to stress
aseline CharacteristicsTable 1 Baseline Characteristics
All 100 (11,040)
Male 63.7% (7,020/11,017)
Female 36.3% (3,997/11,017)
Age (yrs) 60 (47–70)
BMI (kg/m2) 26.2 (23.7–29.4)
Field
1.0-T 1.1% (116/11,002)
1.5-T 98.2% (10,801)
3.0-T 0.8% (85)
Stress
No stress 68.5% (7,565/11,040)
Adenosine 20.9% (2,309)
Dobutamine 10.6% (1,166)
Reader
Cardiologist 78.2% (8,619)
Team of cardiologist and radiologist 20.1% (2,215)
Radiologist 1.7% (187)
Primary indication for CMR
Myocarditis/cardiomyopathies 31.9% (3,511/11,026)
Suspected CAD/ischemia in known CAD 30.8% (3,399)
Myocardial viability 14.7% (1,626)
Valvular heart disease 4.8% (531)
Aortic disease 3.4% (372)
Congenital heart disease 1.6% (181)
Ventricular thrombus 1.4% (154)
Cardiac masses 1.2% (129)
Pulmonary vessels 1.1% (126)
Coronary vessels 0.2% (25)
Other than above 8.8% (972)
alues are % (n) or median (quartiles).
BMI  body mass index; CAD  coronary artery disease; CMR  cardiovascular magnetic
esonance.
Complications Related to No StressVersus Stress Cardiovascular Magnetic ResonanTable 2 Complications Relat d to No StressVersus Stress Cardiovascular Magn
Complications* All (n  1,027) No St
None 98.8% (n 10,896) 99.
Mild 1.1% (n 124) 0.
Severe 0.05% (n 5) 0.*See definitions section for details.esting (Table 2). Thus, resting CMR may be as save as
esting echocardiography, despite the fact that more than
8% of CMR studies involved the administration of con-
rast media. Importantly, the procedural safety of CMR is
ot dependent on race, sex, or age of patients.
However, one important limitation of our data concerning
MR safety may be that patients did not undergo systematic
linical follow-up, and, thus, theoretically possible cases of
ephrogenic systemic fibrosis may have been missed despite
he fact that our mean dose of contrast media was low (1.28
mol/kg), and we did repeatedly contact the participating
enters but did not receive any reports of nephrogenic systemic
brosis. Nevertheless, serum creatinine and glomerular filtra-
ion rate should be evaluated and taken into account before any
adolinium contrast administration.
Since most complications of stress CMR are not related
o CMR imaging itself, but to stressing the patient, stress
MR is likely to be as safe as stress echocardiography (24),
tress nuclear testing (25), or even as safe as obtaining a
imple treadmill electrocardiogram (about 1 fatal complica-
ion or myocardial infarction in 2,500 cases) (26).
mage quality in the clinical routine. To our knowledge,
his is the first dataset on clinical routine image quality of
MR in a multicenter and multivendor setting (Online
Resonance
 7,553) Stress (n  3,474) p Value
7,516) 97.7% (n 3,380) 0.0001
35) 2.5% (n 89) 0.0001
0) 0.2% (n 5) 0.0001
ndications, Image Quality, andomplications Related to P tient AgeTable 3 ndications, Im g Quality, andComplications Related to Patient Age
Age
44 Yrs 45–59 Yrs 60–74 Yrs 75 Yrs
Indication
Ischemia/CAD 10.1% 32.3% 39.6% 36.9%
Myocarditis/CMP 58.2% 32.5% 21.2% 14.5%
Viability 4.5% 15.5% 17.9% 21.5%
Stress CMR 22.2% 22.7% 40.2% 37.7%
Image quality
Good 94.6% 92.8% 88.5% 81.3%
Moderate 4.5% 6.0% 9.5% 15.2%
Poor 0.9% 1.2% 2.0% 3.6%
Ectopy 72.2% 37.1% 42.1% 28.9%
Atrial fibrillation 27.8% 62.9% 57.9% 71.1%
Complications*
None 99.2% 98.9% 98.6% 98.5%
Mild 0.8% 1.0% 1.4% 1.3%
Severe 0% 0.2% 0% 0.1%
New diagnosis 18.3% 17.1% 15.8% 12.9%
Therapeutic consequence 29.2% 42.4% 49.3% 53.2%
See definitions section for details.
CMP  cardiomyopathy; other abbreviations as in Table 1.ce
etic
ress (n
5% (n
5% (n
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October 6, 2009:1457–66 EuroCMR Registry Pilot Resultsppendix). Our data demonstrate that CMR was capable of
nswering the relevant clinical questions in more than 98%
f cases. This indicates that current CMR utilization yields
high number of valuable studies, which is related to the
ood image quality. Only 1.8% of studies were inadequate
n quality, allowing no diagnosis.
Importantly, this was shown in a clinical routine setting,
ince patients with dyspnea at rest, atrial fibrillation, obesity
body mass index quartiles 23.7 to 29.4 kg/m2), or other
requent cardiac conditions affecting image quality were not
xcluded. Thus, the average image quality of CMR may be
etter than the average image quality of other noninvasive
maging techniques, such as echocardiography (27), cardiac
omputed tomography (28,29), or SPECT (30). In addi-
ion, no ionizing radiation needs to be applied during
MR, so it can therefore be repeated as often as necessary
or follow-up purposes.
However, we found a significant decrease of image
uality in older patients, which interestingly was associ-
mpact of CMR on Patient ManagementTable 4 Impact of CMR on Patient Management
All 100% (11,040)
Completely new diagnosis not suspected before 16.4% (1,748/10,672)
Therapeutic consequences
Change in medication 23.5% (2,462/10,464)
Intervention/surgery 8.7% (912)
Invasive angiography/biopsy 8.7% (909)
Hospital discharge 2.2% (231)
Hospital admission 0.3% (36)
Impact on patient management (new diagnosis
and/or therapeutic consequence)
61.8% (6,589)
Noninvasive imaging ordered after CMR
Transthoracic echocardiography 11.9% (1,228/10,346)
Transesophageal echocardiography 0.9% (97)
Computed tomography 0.9% (96)
alues are % (n).
CMR  cardiovascular magnetic resonance.
Impact of CMR on Patient Management by IndicTable 5 Impact of CMR on Patient Managem
Myo
All (from n  11,040)
Completely new diagnosis not suspected before
Therapeutic consequences
Change in medication
Intervention/surgery
Invasive angiography/biopsy
Hospital discharge
Hospital admission
Impact on patient management (new diagnosis
and/or therapeutic consequence)
Noninvasive imaging ordered after CMR
Transthoracic echocardiography
Transesophageal echocardiography
Computed tomographyAbbreviations as in Tables 1 and 3.ted with an increased impact on patient management in
his group (Table 3). This can most probably be ex-
lained by the increased morbidity in older patients
ausing more gating or breathing problems, but also
ielding more abnormal findings requiring an altered
anagement (Table 3).
mpact of CMR on patient management in the clinical
outine. We found that CMR was capable of satisfying all
maging needs in more than 86% of patients so that no
urther noninvasive imaging procedure was required after
ompletion of CMR. Interestingly, in the subgroup of
atients with no other imaging test before CMR (23.1%),
ll imaging needs were also satisfied by CMR in the
ajority of cases (80.4%). This finding underscores that the
ow rate of additional tests ordered after completed CMR is
ot due to the fact that CMR is the last test in a long row
f diagnostic procedures, but rather can answer multiple
mportant questions within 1 exam. Furthermore, CMR
ad direct impact on the clinical management of the
ajority of patients (Tables 4 and 5). Importantly, in
atients in whom CMR was the only imaging test per-
ormed, nearly three-quarters (74.2%) of CMR procedures
ad direct impact on patient management. Thus, based on
he pilot data of the EuroCMR registry, the potential of
MR imaging in the clinical routine is now well docu-
ented in a multicenter and multivendor setting.
In patients undergoing CMR stress testing for workup of
uspected CAD (Table 6), invasive angiography could be
voided in nearly one-half of the patients (n  1,509).
onsequently, CMR stress testing for risk stratification in
uspected CAD may have the potential to significantly
ring down the number of diagnostic coronary angiogra-
hies that do not result in intervention or surgery in the
uture (31–33). In addition, nearly 700 noninvasive proce-
ures involving the use of ionizing radiation, such as
PECT imaging, could also be avoided on the basis of the
MR results (Table 6).
by Indication
is/CMP Suspected CAD/Ischemia Viability
8% 30.8% 14.7%
19.6% 7.9%
7% 25.9% 34.4%
9% 6.7% 17.7%
3% 15.6% 6.1%
7% 3.6% 2.2%
4% 0.2% 0.3%
0% 71.2% 68.6%
9% 6.3% 10.9%
4% 0.4% 0.3%
6% 0.8% 1.1%ationent
cardit
31.
21%
22.
2.
6.
1.
0.
55.
16.
0.
0.
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nto the clinical routine. However, given the reduced need
or further imaging, or other diagnostic procedures in
ombination with the large percentage of altered patient
anagement after CMR, it is likely that integrating CMR
nto the clinical routine does not increase the overall costs of
atient care.
linical implications. On the basis of the registry find-
ngs, one could speculate that an increased routine use of
MR could have an effect on the number of invasive
rocedures, as well as on the numbers of SPECT scans in
he future. Echocardiography with its flexibility, speed, and
Diastole
C
M
R
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m
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g
AVA 1.3cm2
Congo red staining 
H
is
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lo
gy
Figure 5 Completely New Diagnosis by CMR
Steady state free precession cine (diastole, systole, and aortic valve area [AVA]),
workup of heart failure, and discrepant previous findings regarding possible aortic
be 1.3 cm2, contrast CMR (LGE) revealed diffuse subendocardial enhancement in
osis. After CMR, this diagnosis was confirmed by endomyocardial biopsy (bottom
Additional Diagnostic Procedures Avoided Due tTable 6 Additional Diagnostic Procedures A
All (n  10,284) No S
Invasive angiography 21.5% (2,213)
Nuclear (SPECT/PET) 9.0% (928)
Coronary CT 2.0% (204)
Values are % (n).
CMR cardiovascular magnetic resonance; CT computed tomography; P
tomography.ow associated costs will probably remain the imaging
echnique of first choice in most patients as recommended
y current guidelines (34), which is also reflected by the fact
hat the majority of registry patients underwent echocardi-
graphy before CMR. However, CMR can add to echocar-
iographic findings, especially in the workup of cardiomy-
pathies and myocarditis (17,35), suspected CAD (14), as
ell as myocardial viability (13).
Despite our promising results, however, it is important to
eep in mind that most of the parameters describing the
mpact of CMR on patient management collected during the
ilot phase of the EuroCMR registry are all more or less
Systole
E LGE
Cross polarized light  
l as contrast-enhanced CMR (LGE) images of a 78-year-old man presenting for
is. Whereas steady-state free precession CMR sufficiently assessed the AVA to
rge parts of the left ventricle (white arrows), which is typical for cardiac amyloid-
bbreviations as in Figure 3.
sults of CMRd Due to Results of CMR
(n  6,933) Stress (n  3,351) p Value
(704) 45.0% (1,509) 0.0001
(319) 18.2% (609) 0.0001
(131) 2.2% (73) 0.32LG
as wel
stenos
the la
row). Ao Revoide
tress
10.2%
4.6%
1.9%ET positron emission tomography; SPECT single-photon emission
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October 6, 2009:1457–66 EuroCMR Registry Pilot Resultsrecise surrogate parameters for the impact of CMR imaging
n a patients prognosis. Thus, an important next step is to
xpand the EuroCMR registry to collect prognostic data on a
uropean multicenter, and multivendor level (Fig. 1), begin-
ing with the most important indications based on the results
f this pilot data. As soon as sufficient prognostic data is
vailable, CMR may hold promise to reshape cardiovascular
atient management in the future. Thus, in April 2009 we
ave started to implement the following 3 first specific proto-
ols on a European level.
USPECTED CAD. Using the combined information from wall
otion, ischemia, and scar detection, CMR yields a diagnostic
erformance for the detection of CAD similar to SPECT or
tress echocardiography (2,4). However, compared with
PECT and stress echocardiography, there is only limited evi-
ence on the prognostic impact of this combined CMR
nformation in the setting of suspected CAD (5,36). Thus, the
ain aim of the first specific protocol initiated by the European
MR registry is to demonstrate that patients presenting for
orkup of suspected CAD that have a completely normal
MR scan will have a low risk for cardiovascular events during
ollow-up.
YPERTROPHIC CARDIOMYOPATHY (HCM)—SUDDEN CAR-
IAC DEATH. Another clinical problem of high socioeco-
omic concern is HCM, because the average loss of individual
ifetime caused by an HCM-induced lethal event is much
igher than that caused by most other heart diseases, due to the
ommon early manifestation of HCM and the fact that,
specially in young patients, sudden cardiac death sometimes is
he first symptom of the disease (37). Recently, it has been
escribed that the amount of myocardial scarring detected by
MR is related to the long-term clinical outcome, and may
hus be a much better predictor of lethal events than individual
linical markers (38), which are limited by low positive predic-
ive values (39,40). Consequently, the main aim of the second
pecific protocol initiated by the European CMR registry will
e to evaluate CMR for risk stratification in HCM patients.
ONGESTIVE HEART FAILURE—PROGNOSIS. Ischemic as
ell as nonischemic heart failure are major health burdens in
estern countries. CMR can differentiate etiologies of heart
ailure and (7), thus, guide therapy. It has a high accuracy and
eproducibility for the assessment of left ventricular volumes,
unction, and mass and might, thus, be a superior tool for
uiding therapeutic strategies than echocardiography (2). In
ddition, the presence and extent of scar tissue have been
hown to be important and independent parameters for cardiac
vents (18). However, it is currently unclear which parameters
re best for the prediction of events, how often CMR abnor-
alities are found in “normals,” and which of these findings are
f clinical importance. The main aim of the third specific
rotocol initiated by the European CMR registry will be to
valuate CMR for risk stratification in patients with reduced
jection fraction.tudy limitations. The grading of image quality was based
n the ability of CMR to answer the clinical question the scan
as ordered for. This definition may rather describe the overall
uality of the CMR study than the actual quality of images
ith regard to artefacts.
The sample reported in this report may not be representative
o the medical community since all sites participated in the
egistry on a voluntary basis. In addition, despite the fact that
ollowing the American College of Cardiology Foundation/
merican College of Radiology/Society of Cardiovascular
omputed Tomography/SMCR/American Society of Nuclear
ardiology/North American Society for Cardiac Imaging/
ociety for Cardiovascular Angiography and Interventions/
ociety of Interventional Radiology consensus appropriateness
riteria for CMR (8) was regarded mandatory for all sites, there
as no monitoring comparable to a controlled multicenter trial
f those criteria were followed in every patient.
Furthermore, the current registry data do not include a
ead-to-head comparison of CMR to other imaging mo-
alities with regard to diagnostic performance or prognostic
mplications. Thus, the current data cannot be used to make
linical recommendations on these topics.
onclusions
MR is frequently performed in daily clinical practice in
any participating centers. The most important indications
re workup of myocarditis and cardiomyopathies, risk strat-
fication in suspected CAD/ischemia, and assessment of
yocardial viability. CMR imaging as used in the centers of
he pilot registry, is a safe procedure, has diagnostic image
uality in more than 98% of cases, and its results have strong
mpact on patient management.
eprint requests and correspondence: Dr. Oliver Bruder, Elisa-
eth Hospital, Klara-Kopp-Weg 1, 45138 Essen, Germany. E-mail:
.bruder@contilia.de.
EFERENCES
1. Fuster V, Kim RJ. Frontiers in cardiovascular magnetic resonance.
Circulation 2005;112:135–44.
2. Nagel E, Lehmkuhl HB, Bocksch W, et al. Noninvasive diagnosis of
ischemia-induced wall motion abnormalities with the use of high-dose
dobutamine stress MRI: comparison with dobutamine stress echocar-
diography. Circulation 1999;99:763–70.
3. Schwitter J, Nanz D, Kneifel S, et al. Assessment of myocardial
perfusion in coronary artery disease by magnetic resonance: a compar-
ison with positron emission tomography and coronary angiography.
Circulation 2001;103:2230–5.
4. Schwitter J, Wacker CM, van Rossum AC, et al. MR-IMPACT:
comparison of perfusion-cardiac magnetic resonance with single-
photon emission computed tomography for the detection of coronary
artery disease in a multicentre, multivendor, randomized trial. Eur
Heart J 2008;29:480–9.
5. Jahnke C, Nagel E, Gebker R, et al. Prognostic value of cardiac
magnetic resonance stress tests: adenosine stress perfusion and dobut-
amine stress wall motion imaging. Circulation 2007;115:1769–76.
6. Giang TH, Nanz D, Coulden R, et al. Detection of coronary artery
disease by magnetic resonance myocardial perfusion imaging with
various contrast medium doses: first European multi-centre experi-
ence. Eur Heart J 2004;25:1657–65.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
K
m
F
1466 Bruder et al. JACC Vol. 54, No. 15, 2009
EuroCMR Registry Pilot Results October 6, 2009:1457–667. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed
enhancement cardiovascular magnetic resonance assessment of non-
ischaemic cardiomyopathies. Eur Heart J 2005;26:1461–74.
8. Hendel RC, Patel MR, Kramer CM, et al. ACCF/ACR/SCCT/
SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for
cardiac computed tomography and cardiac magnetic resonance imag-
ing: a report of the American College of Cardiology Foundation
Quality Strategic Directions Committee Appropriateness Criteria
Working Group, American College of Radiology, Society of Cardio-
vascular Computed Tomography, Society for Cardiovascular Magnetic
Resonance, American Society of Nuclear Cardiology, North American
Society for Cardiac Imaging, Society for Cardiovascular Angiography
and Interventions, and Society of Interventional Radiology. J Am Coll
Cardiol 2006;48:1475–97.
9. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standard-
ized cardiovascular magnetic resonance imaging (CMR) protocols,
society for cardiovascular magnetic resonance: Board of Trustees Task
Force on Standardized Protocols. J Cardiovasc Magn Reson 2008;
10:35.
0. Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular
magnetic resonance in clinically suspected cardiac amyloidosis: nonin-
vasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol
2008;51:1022–30.
1. Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete
microinfarction after percutaneous coronary intervention associated
with mild creatine kinase-MB elevation. Circulation 2001;103:
2780–3.
2. Wagner A, Mahrholdt H, Holly TA, et al. Contrast-enhanced MRI
and routine single photon emission computed tomography (SPECT)
perfusion imaging for detection of subendocardial myocardial infarcts:
an imaging study. Lancet 2003;361:374–9.
3. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced
magnetic resonance imaging to identify reversible myocardial dysfunc-
tion. N Engl J Med 2000;343:1445–53.
4. Klem I, Heitner JF, Shah DJ, et al. Improved detection of coronary
artery disease by stress perfusion cardiovascular magnetic resonance
with the use of delayed enhancement infarction imaging. J Am Coll
Cardiol 2006;47:1630–8.
5. Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized
myocardial scar detected by cardiac magnetic resonance imaging on
event-free survival in patients presenting with signs or symptoms of
coronary artery disease. Circulation 2006;113:2733–43.
6. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC,
Pennell DJ. Toward clinical risk assessment in hypertrophic cardio-
myopathy with gadolinium cardiovascular magnetic resonance. J Am
Coll Cardiol 2003;41:1561–7.
7. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart
failure related to dilated cardiomyopathy and coronary artery disease
using gadolinium-enhanced cardiovascular magnetic resonance. Cir-
culation 2003;108:54–9.
8. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic
resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am
Coll Cardiol 2006;48:1977–85.
9. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic
resonance assessment of human myocarditis: a comparison to histology
and molecular pathology. Circulation 2004;109:1250–8.
0. Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of
myocardial damage, and clinical course of viral myocarditis. Circula-
tion 2006;114:1581–90.
1. Friedrich MG, Strohm O, Schulz-Menger J, Marciniak H, Luft FC,
Dietz R. Contrast media-enhanced magnetic resonance imaging
visualizes myocardial changes in the course of viral myocarditis.
Circulation 1998;97:1802–9.
2. Cheng AS, Pegg TJ, Karamitsos TD, et al. Cardiovascular magnetic
resonance perfusion imaging at 3-tesla for the detection of coronary
artery disease: a comparison with 1.5-tesla. J Am Coll Cardiol
2007;49:2440–9.
3. Sommer T, Hackenbroch M, Hofer U, et al. Coronary MR angiog-
raphy at 3.0 T versus that at 1.5 T: initial results in patients suspected
of having coronary artery disease. Radiology 2005;234:718–25. a4. Varga A, Garcia MA, Picano E. Safety of stress echocardiography
(from the International Stress Echo Complication registry). Am J
Cardiol 2006;98:541–3.
5. Gupta NC, Esterbrooks DJ, Hilleman DE, Mohiuddin SM, for the
GE SPECT Multicenter Adenosine Study Group. Comparison of
adenosine and exercise thallium-201 single-photon emission com-
puted tomography (SPECT) myocardial perfusion imaging. J Am Coll
Cardiol 1992;19:248–57.
6. Lee TH, Boucher CA. Clinical practice. Noninvasive tests in patients
with stable coronary artery disease. N Engl J Med 2001;344:1840–5.
7. Jenkins C, Moir S, Chan J, Rakhit D, Haluska B, Marwick TH. Left
ventricular volume measurement with echocardiography: a comparison of
left ventricular opacification, three-dimensional echocardiography, or both
with magnetic resonance imaging. Eur Heart J 2009;30:98–106.
8. Miller JM, Rochitte CE, Dewey M, et al. Diagnostic performance of
coronary angiography by 64-row CT. N Engl J Med 2008;359:2324–36.
9. Budoff MJ, Dowe D, Jollis JG, et al. Diagnostic performance of
64-multidetector row coronary computed tomographic angiography
for evaluation of coronary artery stenosis in individuals without known
coronary artery disease: results from the prospective multicenter
ACCURACY (Assessment by Coronary Computed Tomographic
Angiography of Individuals Undergoing Invasive Coronary Angiogra-
phy) trial. J Am Coll Cardiol 2008;52:1724–32.
0. Berman DS, Kiat H, Van Train KF, Friedman J, Garcia EV, Maddahi
J. Comparison of SPECT using technetium-99m agents and thallium-
201 and PET for the assessment of myocardial perfusion and viability.
Am J Cardiol 1990;66:72E–9E.
1. Johnson LW, Lozner EC, Johnson S, et al. Coronary arteriography
1984–1987: a report of the Registry of the Society for Cardiac
Angiography and Interventions. I. Results and complications. Cathet
Cardiovasc Diagn 1989;17:5–10.
2. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy
with or without PCI for stable coronary disease. N Engl J Med
2007;356:1503–16.
3. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and
stroke statistics—2009 Update. A report from the American Heart
Association Statistics Committee and Stroke Statistics Subcommittee.
Circulation 2009;119:e21–181.
4. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for
the diagnosis and treatment of acute and chronic heart failure 2008:
the Task Force for the Diagnosis and Treatment of Acute and Chronic
Heart Failure 2008 of the European Society of Cardiology. Developed
in collaboration with the Heart Failure Association of the ESC (HFA)
and endorsed by the European Society of Intensive Care Medicine
(ESICM). Eur Heart J 2008;29:2388–442.
5. Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular
magnetic resonance in myocarditis: a JACC white paper. J Am Coll
Cardiol 2009;53:1475–87.
6. Hundley WG, Morgan TM, Neagle CM, Hamilton CA, Rerkpat-
tanapipat P, Link KM. Magnetic resonance imaging determination of
cardiac prognosis. Circulation 2002;106:2328–33.
7. Cannan CR, Reeder GS, Bailey KR, Melton LJ 3rd, Gersh BJ.
Natural history of hypertrophic cardiomyopathy. A population-based
study, 1976 through 1990. Circulation 1995;92:2488–95.
8. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency
of arrhythmias in hypertrophic cardiomyopathy in relation to delayed
enhancement on cardiovascular magnetic resonance. J Am Coll Car-
diol 2008;51:1369–74.
9. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic
cardiomyopathy: identification of high risk patients. J Am Coll Cardiol
2000;36:2212–8.
0. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management
of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775–85.
ey Words: cardiovascular magnetic resonance y registry y patient
anagement y therapeutic implications.
APPENDIX
or detailed information about the participating sites
nd acknowledgments, please see the online version of this article.
